key: cord-0283200-zw82d0us
authors: Roodink, Ilse; van Erp, Maartje; Li, Andra; Potter, Sheila; van Duijnhoven, Sander M J; Kuipers, Arthur J; Kazemier, Bert; van Geffen, Ellen; Hemrika, Wieger; Berkeveld, Bob; Sonnemans, Glenn; de Vries, Britte S; Boers, Bianca; Smits, Milou; Meurs, Sanne; de Pooter, Maaike; Thom, Alexandra; Duplantis, Barry N; Romijn, Roland A; Houser, Jeremy; Bath, Jennifer; Abdiche, Yasmina N
title: Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy
date: 2021-07-21
journal: bioRxiv
DOI: 10.1101/2021.07.20.452858
sha: 2d9df72bc574bc3d6389349eba6480d1810b5008
doc_id: 283200
cord_uid: zw82d0us

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an ongoing global human health crisis and will likely become endemic, requiring novel sustainable therapeutic strategies. We report on the discovery of a fully human multi-antibody cocktail (TATX-03) targeting diversified non-overlapping epitopes on the SARS-CoV-2 spike protein that suppressed replication-competent viral titers to undetectable levels in the lungs of SARS-CoV-2 challenged hamsters upon both prophylactic and therapeutic administration. While monotherapy with two of the individual cocktail components also showed clear in vivo protection, neither recapitulated the efficacy of TATX-03. This synergistic effect was further supported by examining in vivo efficacy of these individual antibodies and corresponding combination therapy at a lower dose. Furthermore, in vitro screenings using VSV-particles pseudo-typed with spike proteins representing the SARS-CoV-2 variants of concern Alpha, Beta, and Delta showed that TATX-03 maintained its neutralization potency. These results merit further development of TATX-03 as a potential therapy for SARS-CoV-2 infection with resistance to mutagenic escape.

The surface glycoprotein (spike protein or S protein) of SARS-CoV-2 is the mediator of host cell 28 attachment and entry and is indispensable for infection 1 . For this reason, most therapeutic 29 monoclonal antibody (Ab) candidates have been directed to the receptor binding domain (RBD) 30 of the S protein to disrupt its interaction with host angiotensin converting enzyme 2 (ACE2) and 31 neutralize host cell entry 2-6 . However, using in vitro neutralization as the main predictor for in 32 vivo protection ignores other potential mechanisms of action that may occur in vivo, including 33

To determine the in vivo efficacy of TATX-03, two blends and their individual constituent Abs 155 were tested in a Syrian hamster model of acute SARS-CoV-2 infection 15, 16 . Blends TATX-03a and 156 TATX-03b were tested in separate studies, with all Abs (or PBS mock) administered as a single 157 intraperitoneal (i.p.) dose either 24-hours pre-challenge (prophylaxis, PPx) or 4 hours post-158 challenge (therapeutic, Tx) with SARS-CoV-2 (D614G Mutant BetaCoV/Munich/BavPat1/2020) 159 (Fig 4a) . Infection was confirmed by PCR on day 1 post-challenge throat swab samples and 160 average daily weight loss was similar for all groups for the duration of the study (Supplemental 161 Fig S5c-d) , which is anticipated to be due to prominent local infections following intranasal inoculation with a significant bolus of virus. Table  176 1 summarizes the various replication-competent viral titers per cohort. 177 178 Histopathological analysis of airway tissues harvested at the day 4 endpoint showed relatively 179 minimal changes in gross pathology (as expected with the study endpoint coinciding with the 180 acute phase of disease), however, the severity/extent of immune cell infiltration was reduced in 181 groups treated with the TATX-03a cocktail compared to mock, resulting in reduced bronchitis and 182 tracheitis severity scores (Fig 5c-d) . cocktail (dosed at 20 mg/kg total Ab, equivalent to 5 mg/kg/Ab). Like TATX-03a, all animals (5/5) 195 treated with the TATX-03b showed undetectable viral titers in lung at the day 4 endpoint. Only 196 high dose monotherapy with 23-H7 or 21-F2 resulted in viral titer reduction in lung comparable to the cocktail in 80% (4/5) of the animals, while viral titer reduction was clearly less pronounced 198 in animals treated with the corresponding low dose monotherapy (Fig 4e, Table 1 ). This indicates 199 that the cocktail's efficacy cannot not solely be attributed to the presence of 23-H7 or 21-F2 200 individually, strongly suggesting a synergistic effect. When dosed as a 2-Ab cocktail (23-H7, 21-201 F2) at 5 mg/kg total Ab concentration (equivalent to 2.5 mg/kg/Ab), viral load in the lung at the 202 day 4 endpoint was reduced to undetectable levels in 60% (3/5) of animals, which was more 203 efficacious than either individual Ab when administered at 5 mg/kg, consistent with a synergistic 204 effect (Fig 4e) . 205 206

To determine whether the components of the TATX-03 cocktail were resistant to SARS-CoV-2 208 as well as the A (Wuhan-1) and B (D614G) parental lineages for reference. These data revealed a 211 bin-dependent susceptibility to viral variants (Fig 6a) , which generally was in line with the data 212 obtained from ELISA-based reactivity screening towards plate-adsorbed recombinant spike 213 variants (Supplement Fig S6a- Delta variants. In addition to the two TATX-03 4-Ab cocktails, a 5-Ab version of TATX-03 (TATX-232 03c) was tested which included two bin 4 antibodies (21-F2 and 22-D9) to potentially capitalize 233 on subtle differences in their binding specificities identified by the epitope binning experiments 234 and VOCs screenings. All analyzed multi-Ab cocktails retained potent neutralization against the 235 tested pseudotyped viruses (Fig 6b) Antibodies may provide significant benefit in treating newly SARS-CoV-2-infected individuals with 244 high-risk for progression to severe disease. To date, four antibody therapeutics targeting the 245 SARS-CoV-2 spike protein have received emergency use authorization (two monoclonal 246 antibodies, and two two-Ab combination therapies). However, the exquisite specificity of Abs 247 also renders them susceptible to mutagenic escape. Combining Abs into multi-Ab cocktails in 248 order to broaden the aggregate epitope footprint by targeting diversified epitopes is anticipated 249 to significantly reduce this mutagenic escape risk. Here, we have demonstrated the use of pre-250 existing fully human B cell libraries to rapidly identify a highly diverse panel of SARS-CoV-2 spike 251 protein-specific Abs for curation into therapeutic cocktails capable of resisting mutagenic escape. 252 253 Intriguingly, the pair of RBD-specific binders used in our TATX-03 cocktail (bin 2 + bin 4) target 254 similar epitopes as those incorporated in dual therapies with reported in vivo efficacy that have 255 been discovered independently by other groups; REGN10987 (overlaps our bin 2) + REGN10933 256 (overlaps our bin 4); CoV2-06 + CoV2-14; and COV2-2130 + COV2-2196 6;18-21 . While this suggests 257 that only particular combinations of Abs will produce in vivo protection, these therapies are more 258 susceptible to mutagenic escape and may only utilize neutralization as the primary mechanism 259 of action. To our knowledge, we are the first to report on the discovery of a multi-Ab cocktail, 260 beyond a dual therapy, that produces in vivo protection against SARS-CoV-2 via synergistic effects 261 in an animal model of infection. 262

Authentic virus neutralization assays are often used as a triage step for prioritizing Abs for in vivo 264 studies, however, by this criteria, 23-H7 would have been overlooked. Since we intentionally 265 retained high functional diversity in our leads, we progressed this clone due to its uniquely high 266 affinity, kinetic perturbation/partial blockade of ACE2 binding, potency in pseudovirus assay and 267 ability to pair with other neutralizing and non-neutralizing bins in cocktails. This resulted in its 268 prioritization for in vivo testing where it was highly efficacious as both a monotherapy and in 269 combination with other Abs in prophylactic or therapeutic settings. While the discrepancy 270 between our in vitro pseudovirus-and authentic virus-based neutralization screening data might 271 indicate a bias towards strong ACE2 blocking potency for the latter assay format, the lack of 272 correlation between in vitro neutralization and in vivo protection has been reported by others 7 , 273 and suggests that non-neutralizing mechanisms of action can provide therapeutic benefit. We 274 anticipate that the high human IgG1 decoration degree of the spike trimer, resulting from 275 simultaneous binding of the individual cocktail components, contributes to in vivo viral load 276 reduction by enhancing Fc-mediated clearance. 277

The breadth of our discovery approach not only resulted in opportunities for combining multiple 279

Abs across distinct non-overlapping bins, but also enabled us to leverage nuanced intra-bin 280 variations, facilitating rapid reformulation of cocktails in response to mutations or seasonal 281 variations in the SARS-CoV-2 genome. Indeed, our detailed binning analysis suggested that 22-282 D9 and 21-F2 bind different, but overlapping epitopes, which was corroborated by their 283 differential susceptibility to cell-associated spike of the B.1.526 lineage, so we retained both in a 284 5-Ab cocktail formulation to provide a broader resistance to viral variants, while retaining potent 285 neutralization via synergistic effects. A similar compensation strategy was likely the rationale for 286 combining bamlanivimab and etesevimab, which bind different but overlapping epitopes on 287 RBD 9 . However, applying this strategy to a dual therapy, resulting in a "refined" monotherapy 288 that is still vulnerable to escape by a single point mutation. Ab cocktail to retain efficacy towards an evolving viral genome, meriting its investigation in the 295 clinic as a potential therapeutic intervention for SARS-CoV-2 infection. 296

Recombinant proteins 300

Various targets were used as panning, screening and analytical reagents for ELISA and Octet 301 binding assays and purchased from different vendors. SARS-CoV-2 spike trimer, RBD-hFc, RBD 302 (tagless), human ACE2-hFc, and SARS-CoV-1 spike trimer were produced using the rPEx TM 303 recombinant protein production platform. In brief, HEK293-EBNA1 cells were transiently 304 transfected with pUPE expression vectors containing recombinant protein encoding, codon-305 optimized synthetic genes. Six days post transfection secreted recombinant proteins were 306 purified to homogeneity by a two-step purification approach, including affinity purification and 307 from the National Research Council (Quebec, Canada). SARS CoV-2 full-length spike protein and 309 including S1-mFc, S1-hFc, S2-hFc, NTD-hFc, S1-S2-His, S1-His, and mutants S1-His(D614G), S. blocked in PBS + 5% skim milk and any bead-reactive Abs were depleted by pre-incubation with 347 uncoated beads. Unbound phages were subsequently incubated with the antigen-coated beads, 348 followed by washing in PBS-Tween to remove any unbound phage particles. Depending on the 349 panning strategy, either the bead-bound (for positive antigen selection) or unbound (for negative 350 selection) phage particles were incubated with TG1 cells followed by phage rescue by helper 351 phage superinfection. For target enrichment, eleven unique panning strategies were conducted in parallel using varying combinations of S1, S2, and RBD subunits of the SARS-CoV-2 spike 353 protein, and a fully assembled, stabilized spike trimer of the related SARS-CoV-1). Depletion 354 panning with human ACE2-or CR3022-bound spike (where CR3022 represents an anti-SARS-CoV-355 1 antibody from the literature with cross-reactivity to SARS-CoV-2 23,27 ) and irrelevant non-target 356 proteins were performed to steer towards binders to specific epitopes and increase target 357 specificity by reducing off-target reactivity, respectively. 358

Targets diluted to final concentrations 1.5 µg/ml in carbonate binding buffer were added to 361

Greiner Bio-One High Bind ELISA plates in 50 µL/well and incubated overnight at 4°C. Plates were 362 blocked with 1% BSA in PBS for 60 minutes. If an additional capture step was performed it was 363 conducted in PBS for 1 hour at room temperature (RT). Coated plates were finally washed with 364 PBS-T before serial dilutions of phage or recombinant Abs were added in duplicate in PBS 365 supplemented with 5% skim milk or 1% BSA and incubated at RT for 60 minutes. After washing 366 with PBS-T, appropriate HRP-conjugated secondary antibody (anti-M13 and goat-anti-human-IgG 367 for detection of phages and full size hIgG1, repsectively) was added and incubated for 60 minutes 368 at RT. For the initial reactivity screenings of scFv-containing periplasmic fraction, target-bound 369 scFvs were detected by incubation with mouse anti-VSV followed by anti-mouse IgG-HRP. After 370 final washing wells were typically stained with 50 µL TMB substrate for 10 minutes and the 371 reaction was stopped by adding 50 µL 2M H2SO4. Absorbance was read at 450 nm on an Envision 372 multimode plate reader and data was processed in GraphPad Prism. 373

All label-free interaction analyses were performed on an Octet HTX biolayer interferometry-376 based detection system (ForteBio/Sartorius, Gottingen, Germany) equipped with various sensor 377 types; AR (amine-reactive), SAX (streptavidin-coated), or AHC (anti-human-Fc capture) sensors. 378

Experiments were conducted at 25°C in a run buffer of PBS + 0.05% Tween-20 + 0.1% BSA. 379 380 Binding affinity estimates 381 Different assay formats were used to estimate the binding affinities of Ab/target bimolecular 382 interactions. In one assay format, Fab was titrated as monovalent analyte (typically as a 3-fold 383 dilution series with a top concentration of 3 µM, and at least one concentration in duplicate) over 384 AHC sensors coated with human-Fc-fused targets RBD-hFc, S1-hFc or S2-hFc as ligands (Sino 385 Biological). In the reverse format, tagless RBD or S1-His(D614G) were titrated as monovalent 386 analytes over Ab-coated AHC sensors. Global affinity estimates were determined using the 387

Kinetics module of Fortebio's Data Analysis HT software version 12.0.1.55. Data were processed 388 by subtracting the responses of a buffer analyte sample and fitting these referenced data globally 389 to a simple 1:1 Langmuir binding model to deduce the KD value from the ratio of the kinetic rate 390 constants (KD = kd/ka), where kd and ka are the dissociation and association rate constants, 391 respectively. Interactions showing square-shaped binding curves were alternatively fit to a 392 steady-state (equilibrium) isotherm; affinities deduced from kinetic and equilibrium fitting 393 routines were equivalent. 394

Additionally, the solution affinity of the 23-H7-Fab/RBD binding interaction was determined by 396 titrating 23-H7 Fab (1000-1.4 nM, as a 7-membered 3-fold dilution series) into RBD fixed at 5 nM, 397 allowing these solutions to equilibrate (an hour at RT) and then probing for free RBD in these 398 samples using SAX sensors coated with biotinylated-23-H7-IgG. All samples were measured on 399 duplicate sensors. An apparent solution affinity (or IC50 value) was determined by fitting the 400 reference-subtracted responses (from a buffer analyte sample) to a non-linear regression, 401 inhibition dose-response curve (4-parameter least-squares fit) model in GraphPad Prism 402 software version 9. 403 404 Pairwise epitope binning 405 Combinatorial pairwise Ab competition or "epitope binning" assays were performed using 406 various assay formats. To perform a "classical sandwich" assay format, Abs were covalently 407 coupled onto AR sensors using standard coupling conditions to generate the ligands (surface-408 immobilized Abs) and used to capture S1-His(D614G) monovalent target (typically 5 µg/ml, 65 409 nM) followed by an Ab analyte typically at 10 µg/ml (133 nM binding sites). Alternatively, reaction 410 surfaces were generated by coating SAX sensors with 5 µg/ml biotinylated Abs. Ligands were 411 regenerated with 75 mM phosphoric acid. "Waterfall" experiments were conducted on freshly 412

Ab-coated SAX sensors (single use, not regenerated) using 5 µg/ml S1-His(D614G) followed by an 413

Ab titration spanning 6000 -25 nM binding sites as a 6-membered 3-fold dilution series, with one 

To perform a "tandem cocktail" multi-Ab binning experiment, SAX sensors were coated with 5 420 µg/ml biotinylated 23-H7 (bin 2) and used to tether 5 µg/ml spike trimer. Three Ab analytes from 421 non-overlapping bins were associated in consecutive analyte binding steps, each step building 422 upon the complex formed in the previous steps. For example, bin 4 Ab was used in step 1, bin 423 4+C was used in step 2, and bin 4+C+S2 was used in step 3, thereby maintaining saturating levels 424 of the Ab analyte applied in the previously applied steps to eventually saturate the 23-H7-425 tethered spike with three Ab analytes (from bins 4, C and S2). The responses of each newly 426 applied Ab analyte to "Ab-saturated" 23-H7-tethered spike were compared with the responses 427 of that Ab analyte to the "naked" 23-H7-tethered spike. Data were processed in ForteBio's Data 428 for a pairwise analysis of 19 library-derived anti-SARS-CoV-2 S1-specific Abs merged with a panel 548 of ten structural benchmarks (9 literature Abs and ACE2). The red, yellow, and green colored cells 549

indicate Ab pairs that are blocked (b), partially blocked (pb), or not blocked (nb), respectively. 550

Colored cells with a designation of "b, pb, or nb" were measured empirically, whereas those 551 without a designation are "inferred". The black boxed cells along the diagonal indicate the "self-552 blocked" pairs. In our bin-definition, bin-members block one another and show similar blocking 553 behaviors when tested against other Abs in the panel. RBD-specific clones were assigned to five 554 bins (1) (2) (3) (4) (5) . RBD binders that did not block ACE2 were assigned bin "1", which was split into sub-555 bins (bin 1a, 1b, and 1c) based on their nuanced blockade towards the structural benchmarks 556 (Supplemental Fig S1) . A cluster of S1 non-RBD binders blocked bin 1 (but not the sub-bins) and 557 did not block any of the literature Abs, so were assigned to bin "C", representing the C-terminal 558 nub of the S1 fragment, between the RBD and the furin cleavage site, distinct from the N-terminal 559 domain (NTD); hence, bin C's specificity is assigned as S1-nonRBD-nonNTD. One RBD-binder Ab 560 (23-H7) blocked bin 1, REGN10987 and uniquely perturbed/partially blocked ACE2 561 (Supplemental Fig S2) , so was assigned to bin 2. Within the ACE2 fully blocking clones, we 562 identified two discrete sets of Abs (bin 4 and bin 5); bin 4 co-located with REGN10933 and CB6, 563 while bin 5 co-located with the "cryptic" epitope of CR3022, VHH-72 and SB68. Bin 3 blocked 564 both bin 2 (23-H7) and bin 4. shown in Supplemental Fig 6a. (b) In vitro virus neutralization screenings of TATX-03a-c c using 633 VSV-particles pseudo-typed with spike proteins representing the original Wuhan-1 isolate and 634 SARS-CoV-2 variants of concern Alpha, Beta, and Delta.. His(D614G) that is tethered via ACE2-coated sensors (left) showing that 23-H7 binding is 651 kinetically perturbed (partially blocked) suggesting that 23-H7 and ACE2 target closely adjacent 652 or minimally overlapping epitopes, whereas 22-D9 is fully blocked, suggesting that its epitope 653 may overlap substantially with that of ACE2. Dose-dependent unhindered sandwiching signals of 654 S1-His(D614G) tethered via anti-His mAb-coated sensors (right) serve as controls to indicate the 655 results expected for analyte binding at a distinctly different and non-overlapping site relative to 656 that of the immobilized binding partner on the sensor. Ligand and analyte refer to the binding partner used "on sensor" or "in solution", respectively. 705 n/d = kinetics not determined for steady-state analysis or solution affinity measurements 706 *Orientations a,b,c refer to those described in Supplemental Fig S4. Pre-mixed antibody cocktails with spike trimer All 1, 2, 3, and 4 Ab combinations b. Figure S2 a.

AHC Sensor RBD-hFc S1-hFc S2-hFc 

Angiotensin-converting enzyme 2 is a functional 711 receptor for the SARS coronavirus

Key residues of the receptor binding motif in the spike protein 714 of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Antibody neutralization of SARS-CoV-2 through ACE2 receptor 717 mimicry

A human neutralizing antibody targets the receptor-719 binding site of SARS-CoV-2

A noncompeting pair of human neutralizing antibodies 722 block COVID-19 virus binding to its receptor ACE2

Studies in humanized mice and convalescent 725 humans yield a SARS-CoV-2 antibody cocktail

Antibody potency, effector function, and combinations in protection and 728 therapy for SARS-CoV-2 infection in vivo

CoV-2 spike protein variants

Revealing the threat of emerging SARS-CoV-2 732 mutations to antibody therapies

Complete map of SARS-CoV-2 RBD 735 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with

Development of a Human Antibody Cocktail that 738

Deploys Multiple Functions to Confer Pan-Ebolavirus Protection

Suptavumab for the Prevention of 741

Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants

A Monoclonal Antibody Combination against 747 both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig 748 Model

Defining the Syrian hamster as a highly susceptible preclinical model for 750 SARS-CoV-2 infection

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Robust SARS-CoV-2 infection in nasal turbinates after treatment with 754 systemic neutralizing antibodies

Molecular determinants and mechanism for antibody cocktail preventing 756 SARS-CoV-2 escape

Potently neutralizing and protective human antibodies against SARS-CoV-758 2

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational 760 escape seen with individual antibodies

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus 762 macaques and hamsters

Antibodies Targeting Closely Adjacent or Minimally Overlapping 764

Epitopes Can Displace One Another

A highly conserved cryptic epitope in the receptor binding domains of 766 SARS-CoV-2 and SARS-CoV

Structural Basis for Potent Neutralization of Betacoronaviruses by 768 Single-Domain Camelid Antibodies

Sybodies targeting the SARS-CoV-2 receptor-binding domain

Human Monoclonal Antibody Combination against SARS 775 Coronavirus: Synergy and Coverage of Escape Mutants

A human monoclonal antibody blocking SARS-CoV-2 infection

A simple method of estimating fifty per cent endpoints

Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-783 PCR